tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Positive Outlook for Ovid Therapeutics: Buy Rating Supported by Promising OV329 Drug and Strategic Pipeline Development
PremiumRatingsPositive Outlook for Ovid Therapeutics: Buy Rating Supported by Promising OV329 Drug and Strategic Pipeline Development
1M ago
Ovid Therapeutics to host investor, media event on June 12
Premium
The Fly
Ovid Therapeutics to host investor, media event on June 12
1M ago
Ovid Therapeutics Reports Q1 2025 Financial Results
Premium
Company Announcements
Ovid Therapeutics Reports Q1 2025 Financial Results
2M ago
Ovid Therapeutics sees cash runway into 2H26
PremiumThe FlyOvid Therapeutics sees cash runway into 2H26
2M ago
Ovid Therapeutics Advances Pipeline Amid Financial Progress
Premium
Company Announcements
Ovid Therapeutics Advances Pipeline Amid Financial Progress
3M ago
Ovid Therapeutics price target lowered to $4 from $5 at BTIG
Premium
The Fly
Ovid Therapeutics price target lowered to $4 from $5 at BTIG
4M ago
Ovid Therapeutics’ Cybersecurity Challenges: Navigating IT Risks and Third-Party Dependencies
PremiumCompany AnnouncementsOvid Therapeutics’ Cybersecurity Challenges: Navigating IT Risks and Third-Party Dependencies
4M ago
Ovid Therapeutics sees cash runway into 2H26
Premium
The Fly
Ovid Therapeutics sees cash runway into 2H26
4M ago
Ovid Therapeutics reports Q4 EPS (13c), consensus (17c)
Premium
The Fly
Ovid Therapeutics reports Q4 EPS (13c), consensus (17c)
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100